{"id":1496,"date":"2022-03-31T15:44:52","date_gmt":"2022-03-31T19:44:52","guid":{"rendered":"http:\/\/microsites.engineering.nyu.edu\/cie\/?p=1496"},"modified":"2022-10-02T08:25:09","modified_gmt":"2022-10-02T12:25:09","slug":"rezonn-biosystems-new-approach-for-drug-discovery","status":"publish","type":"post","link":"http:\/\/microsites.engineering.nyu.edu\/cie\/rezonn-biosystems-new-approach-for-drug-discovery\/","title":{"rendered":"2022 Rezonn Biosystems\u2014New Approach for Drug Discovery"},"content":{"rendered":"<p>By: Alara Tuncer<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.f6s.com\/content-resource\/profiles\/2359818_th2.jpg\" alt=\"Rezonn Biosystems\" \/><\/p>\n<p>The pharmaceutical industry is a multi-billion dollar industry that relies on the consistent<br \/>\ndiscovery and development of new drugs for existing and emerging diseases. Co-founded by Dr.<br \/>\nIwao Teraoka and Natalie H. Luo, Rezonn Biosystems aims to introduce a new technology that<br \/>\nuses a \u201cphotonic sensor system\u201d to conduct \u201clabel-free high-throughput drug screening and in-<br \/>\nvitro diagnostics\u201d for this industry. This novel system utilizes enzymes\u2014protein<br \/>\ncatalysts\u2014whilst monitoring resonance wavelength to infer information about the critical<br \/>\ninteraction between the substrate and the inhibitor. In other words, this method allows<br \/>\nquantifying the relationship between two molecules to screen for numerous drugs.<\/p>\n<p>Rezonn Biosystems have learned a lot about entrepreneurship by participating in NSF\u2019s I-Corps.<br \/>\nThe founders highlight the importance of being \u201c200% confident on the core technology before<br \/>\npushing too hard on pilot or any form of collaboration.\u201d Although their overall goal remains the<br \/>\nsame, \u201cto provide a transformative label-free biosensing platform for early drug discovery &amp;<br \/>\ndevelopment in biopharma and lab diagnostics,\u201d they had to pivot their idea slightly from the<br \/>\noriginal vision to create a product that better fits the market\u2019s needs.<\/p>\n<p>&nbsp;<\/p>\n<p>After participating in NSF\u2019s I-Corps and conducting market research and consumer interviews<br \/>\nthe founders have advice for entrepreneurs transitioning from academia and just starting their<br \/>\njourney to launch their idea. \u201cMake sure there\u2019s a good market fit,\u201d and the founders go on to<br \/>\nexplain that \u201cyou need not only to know that there\u2019s an audience but those who are willing to pay<br \/>\nfor what you are offering.\u201d So instead of pouring all resources into pilots that may eventually<br \/>\nlead to the final product, it is essential to understand what the market values before spending on<br \/>\ncreating the product.<\/p>\n<p>\u201cYou need to find the real unmet need where your idea\/product could make an impact.\u201d It is also<br \/>\nessential to consider \u201chow practical and sustainable it is.\u201d The founders add that this product can<br \/>\nonly be made into reality with the help of a great team that is \u201con the same page in terms of<br \/>\ncommitment because things don\u2019t happen overnight.\u201d On top of that, \u201ca robust support network\u201d<br \/>\ncompromising of \u201cmentors, advisors, network, and community will help you get to where you<br \/>\nneed to be.\u201d<\/p>\n<p>Primarily, \u201cyou have to enjoy it because it\u2019s a lot of hours. If your motivation is entirely based on<br \/>\nan expected payout, you\u2019re going to bail as soon as things look bad.\u201d This is why the co-founders<br \/>\ndefine personal success as \u201cbeing able to cope with failure and learn from it.\u201d They go on to<br \/>\nexplain that they are \u201cstill tackling the problems one-by-one. At this moment, overcoming the<br \/>\ntechnical faults is a huge success.\u201d This will be followed by \u201caccelerat[ing] growth and<br \/>\ncommercializ[ing] new offerings.\u201d<\/p>\n<p>Just like many other start-ups at the beginning stage, the cofounders of Rezonn Biosystems<br \/>\nanticipate many challenges as they move forward with their product. Firstly, in the form of<br \/>\n\u201cfunding and resources,\u201d but also to \u201ccultivate relationships throughout all the different stages of<br \/>\nthe business.\u201d Although, the pandemic has made this difficult, as the founders define confidence<br \/>\nas a key in all grounds from R &amp;amp; D to business operation,\u201d the co-founders have spent more<br \/>\neffort taking the initiative to connect with people and potential funders.Finally, the founders conclude by saying \u201cconstantly listen and converse with potential users,<br \/>\nthen target the weakness\/pain point of competitors\u2019 products and feedback\u201d and revamp the pilot.<br \/>\n\u201cLearn from\u201d everyone you speak to or get feedback from. \u201cIt doesn\u2019t matter how good you are,<br \/>\nbecause you can\u2019t cover everything yourself\u201d and other perspectives are going to strengthen your<br \/>\nproduct and business.<\/p>\n<figure id=\"attachment_1498\" aria-describedby=\"caption-attachment-1498\" style=\"width: 277px\" class=\"wp-caption alignleft\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-1498 size-full\" src=\"http:\/\/microsites.engineering.nyu.edu\/cie\/wp-content\/uploads\/sites\/8\/2022\/03\/unnamed.png\" alt=\"\" width=\"277\" height=\"273\" \/><figcaption id=\"caption-attachment-1498\" class=\"wp-caption-text\">Natalie H. Luo<\/figcaption><\/figure>\n<figure id=\"attachment_1497\" aria-describedby=\"caption-attachment-1497\" style=\"width: 289px\" class=\"wp-caption alignleft\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-1497 \" src=\"http:\/\/microsites.engineering.nyu.edu\/cie\/wp-content\/uploads\/sites\/8\/2022\/03\/unnamed-1.png\" alt=\"\" width=\"289\" height=\"268\" \/><figcaption id=\"caption-attachment-1497\" class=\"wp-caption-text\">Iwao Teraoka, Ph.D.<\/figcaption><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>By: Alara Tuncer The pharmaceutical industry is a multi-billion dollar industry that relies on the consistent discovery and development of new drugs for existing and emerging diseases. Co-founded by Dr. [&hellip;]<\/p>\n","protected":false},"author":37,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1496","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"http:\/\/microsites.engineering.nyu.edu\/cie\/wp-json\/wp\/v2\/posts\/1496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/microsites.engineering.nyu.edu\/cie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/microsites.engineering.nyu.edu\/cie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/microsites.engineering.nyu.edu\/cie\/wp-json\/wp\/v2\/users\/37"}],"replies":[{"embeddable":true,"href":"http:\/\/microsites.engineering.nyu.edu\/cie\/wp-json\/wp\/v2\/comments?post=1496"}],"version-history":[{"count":10,"href":"http:\/\/microsites.engineering.nyu.edu\/cie\/wp-json\/wp\/v2\/posts\/1496\/revisions"}],"predecessor-version":[{"id":1599,"href":"http:\/\/microsites.engineering.nyu.edu\/cie\/wp-json\/wp\/v2\/posts\/1496\/revisions\/1599"}],"wp:attachment":[{"href":"http:\/\/microsites.engineering.nyu.edu\/cie\/wp-json\/wp\/v2\/media?parent=1496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/microsites.engineering.nyu.edu\/cie\/wp-json\/wp\/v2\/categories?post=1496"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/microsites.engineering.nyu.edu\/cie\/wp-json\/wp\/v2\/tags?post=1496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}